The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
Shares of Geron rose almost 16% on Friday before market, a day after getting its first approval from the U.S. Food and Drug ...
Uplizna therapy reaches main goal in Phase 3 trial for IgG4-RD, cutting the risk of flare by 87% with no new safety events.
The FDA's vaccine advisory panel voted to recommend that this fall’s Covid-19 shots should be updated to target Omicron’s ...
Bkemv is the 53rd approved biosimilar in the U.S. The FDA has approved 13 of these as interchangeable biosimilars. It is mandatory for patients to complete meningococcal vaccination before ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
ASCO Annual Meeting kicks off today, showcasing the latest research in cancer therapies to scientists and physicians.
Latest health news includes Louisiana's reclassification of abortion pills as controlled substances, the effectiveness of ...